<DOC>
	<DOCNO>NCT01627002</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability , immunogenicity way body absorbs , distributes , break excrete various increase single multiple subcutaneous dos PA401 healthy subject . This study also look effect PA401 inflammation lung follow inhaled lipopolysaccharide ( LPS ) challenge ( LPS bacterial cell wall fragment ) sputum induction ( procedure perform help cough sputum ( phlegm ) ) single subcutaneous dose two dose level .</brief_summary>
	<brief_title>A Phase 1 , First Human Study Investigate Safety Tolerability PA401</brief_title>
	<detailed_description />
	<criteria>Healthy adult male age 18 65 year Subjects clinically relevant medical history</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>First Human</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Lipopolysaccharide Challenge</keyword>
</DOC>